Acadia Pharmaceutica (ACAD) Stock Price, Quote & News

Company Profile

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimava...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 558 2871

Fax: 858 212 0513

Website: www.acadia.com

Address:

12830 El Camino Real, Suite 400, San Diego, United States

ZacksResearch Feb. 3 at 2:03 PM

Q4 earnings season — these 5 drug & biotech names could surprise to the upside $ZTS, $PCRX, $APLS, $ACAD, and $DNLI are highlighted as poised to beat on fourth-quarter 2025 earnings, setting up a potential outperformance theme investors should have on their radar. See which drug & biotech stocks could deliver earnings upside 👉 https://www.zacks.com/stock/news/2827958/5-drugbiotech-stocks-likely-to-outperform-q4-earnings-estimates?cid=sm-stocktwits-2-2827958-teaser-31624&ADID=SYND_STOCKTWITS_TWEET_2_2827958_TEASER_31624

0 · Reply

ZacksResearch Feb. 3 at 1:16 PM

EU setback looming for $ACAD— Rett syndrome hopes hit pause ⚠️ Acadia expects a negative CHMP opinion on the trofinetide marketing application for Rett syndrome, a move that would delay any potential EU approval. Want the full implications of this regulatory snag? See the details here 👉 https://www.zacks.com/stock/news/2827599/acadia-expects-negative-chmp-opinion-for-rett-syndrome-drug-in-eu?cid=sm-stocktwits-2-2827599-teaser-31596&ADID=SYND_STOCKTWITS_TWEET_2_2827599_TEASER_31596

0 · Reply

ZacksResearch Feb. 3 at 12:16 PM

$ACAD faces a tough road in Europe — will it delay the EU market entry? ⚠️ Acadia expects a negative opinion from the EMA on trofinetide for Rett syndrome, potentially pushing back EU approval. But in the U.S., Daybue continues to gain traction alongside Nuplazid, setting up for long-term growth. Discover the full implications here 👉 https://www.zacks.com/stock/news/2827599/acadia-expects-negative-chmp-opinion-for-rett-syndrome-drug-in-eu?cid=sm-stocktwits-2-2827599-body-31597&ADID=SYND_STOCKTWITS_TWEET_2_2827599_BODY_31597

0 · Reply

Quantumup Feb. 3 at 11:31 AM

Citizens reiterated $ACAD Market Outperform-$34 and said, Likely negative CHMP opinion on the trofinetide MAA for Rett syndrome slows expansion into the EU $TSHA $NGNE $AVXL Citizens added, Yesterday afternoon, Acadia announced a negative CHMP trend vote on its trofinetide MAA for Rett Syndrome after an oral explanation, and the company expects a negative CHMP opinion. The formal CHMP opinion is anticipated later in February, and management intends to seek a re-examination of the opinion should it be unfavorable. While this update is disappointing, exU.S. sales of trofinetide represent potential upside to our model and valuation.

0 · Reply

mikesterz7 Feb. 3 at 2:19 AM

$ACAD Trofinetide is approved by the U.S. Food and Drug Administration to treat Rett syndrome.

1 · Reply

SuperGreenToday Feb. 2 at 10:30 PM

$ACAD Share Price: $26.14 Contract Selected: Sep 18, 2026 $30 Calls Buy Zone: $1.70 – $2.10 Target Zone: $2.71 – $3.31 Potential Upside: 51% ROI Time to Expiration: 227 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

notreload_ai Feb. 2 at 10:19 PM

$ACAD receives negative CHMP vote for trofinetide EU approval despite 1,000+ patients using treatment globally. Company plans re-examination request. https://notreload.xyz/acadia-pharmaceuticals-faces-eu-setback-for-rett-syndrome-drug-trofinetide/

0 · Reply

zeustony88 Feb. 2 at 10:03 PM

$ACAD This company can’t catch a break.

1 · Reply

StocktwitsNews Feb. 2 at 9:33 PM

ACAD Stock Slumps 8% After Hours On Hurdle To EU Approval For Genetic Disorder Drug $ACAD https://stocktwits.com/news/equity/markets/acad-stock-slumps-after-hours-on-hurdles-to-eu-approval-for-genetic-disorder-drug/cZbgCddR4kx

0 · Reply

zeustony88 Feb. 2 at 3:36 PM

$ACAD To those that added shares on the dip!

1 · Reply

Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union

Jan 13, 2026, 4:05 PM EST - 20 days ago

ACADIA Pharmaceuticals Inc. (ACAD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 9:00 AM EST - 21 days ago

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 4:05 PM EST - 6 weeks ago

Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026

Dec 12, 2025, 8:00 AM EST - 7 weeks ago

Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome

Dec 4, 2025, 6:26 PM EST - 2 months ago

Buy Acadia Pharmaceuticals For Daybue/Nuplazid Stability And Pipeline Optionality

Dec 2, 2025, 1:23 PM EST - 2 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Nov 20, 2025, 4:05 PM EST - 2 months ago

Acadia Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference

Nov 10, 2025, 4:31 PM EST - 3 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 6, 2025, 4:36 AM EST - 3 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 4:05 PM EST - 3 months ago

Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview

Oct 28, 2025, 4:05 PM EDT - 3 months ago

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Oct 22, 2025, 3:41 PM EDT - 3 months ago

Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights

Oct 15, 2025, 4:05 PM EDT - 3 months ago

Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025

Oct 6, 2025, 7:30 AM EDT - 4 months ago

ACADIA Pharmaceuticals: Nuplazid And Daybue Are Enough To Remain Bullish

Oct 2, 2025, 9:04 AM EDT - 4 months ago

Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

Sep 24, 2025, 10:05 AM EDT - 4 months ago

Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short

Sep 24, 2025, 7:12 AM EDT - 4 months ago

Acadia Pharmaceuticals' rare disease therapy fails late-stage trial

Sep 24, 2025, 7:00 AM EDT - 4 months ago

Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint

Sep 12, 2025, 4:05 PM EDT - 5 months ago

Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology

Sep 8, 2025, 4:05 PM EDT - 5 months ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 8, 2025, 4:04 PM EDT - 5 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Aug 25, 2025, 4:05 PM EDT - 5 months ago

Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer

Aug 7, 2025, 3:57 AM EDT - 6 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:05 PM EDT - 6 months ago

Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview

Aug 5, 2025, 4:05 PM EDT - 6 months ago

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

Aug 4, 2025, 4:05 PM EDT - 6 months ago

Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer

Jul 28, 2025, 4:32 AM EDT - 6 months ago

Acadia Pharmaceuticals: ACP-101 Read-Out Is Not Fully Priced In

Jul 23, 2025, 4:05 PM EDT - 6 months ago

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025

Jun 25, 2025, 8:00 AM EDT - 7 months ago

Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers

Jun 9, 2025, 4:01 PM EDT - 8 months ago

U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent

Jun 5, 2025, 9:05 AM EDT - 8 months ago

Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025

May 29, 2025, 4:05 PM EDT - 8 months ago

Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

May 27, 2025, 4:05 PM EDT - 8 months ago

Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise

May 19, 2025, 8:25 AM EDT - 9 months ago

These Analysts Boost Their Forecasts On Acadia Pharmaceuticals

May 17, 2025, 10:00 AM EDT - 9 months ago

Acadia Pharmaceuticals: Another Legal Win, ACP-101 Readout Preview

May 16, 2025, 1:43 PM EDT - 9 months ago

Delaware District Court Rules in Favor of Acadia in NUPLAZID® (pimavanserin) Formulation Patent Litigation

May 13, 2025, 12:01 PM EDT - 9 months ago

ACADIA Pharmaceuticals: Advancing On Several Fronts

May 7, 2025, 8:10 PM EDT - 9 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Q1 2025 Earnings Conference Call Transcript

May 7, 2025, 4:05 PM EDT - 9 months ago

Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview

May 5, 2025, 4:05 PM EDT - 9 months ago

Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference

Apr 23, 2025, 4:05 PM EDT - 10 months ago

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025

Mar 5, 2025, 9:05 AM EST - 11 months ago

Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med

Mar 3, 2025, 9:05 AM EST - 1 year ago

Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study

Mar 2, 2025, 5:19 AM EST - 1 year ago

Acadia Pharmaceuticals Ends FY2024 On Solid Footing

Feb 27, 2025, 4:05 PM EST - 1 year ago

Acadia Pharmaceuticals to Participate in the TD Cowen's 45th Annual Health Care Conference

Feb 26, 2025, 8:13 PM EST - 1 year ago

ACADIA Pharmaceuticals Inc. (ACAD) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:05 PM EST - 1 year ago

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Feb 12, 2025, 4:05 PM EST - 1 year ago

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

ZacksResearch Feb. 3 at 2:03 PM

0 · Reply

ZacksResearch Feb. 3 at 1:16 PM

0 · Reply

ZacksResearch Feb. 3 at 12:16 PM

0 · Reply

Quantumup Feb. 3 at 11:31 AM

0 · Reply

mikesterz7 Feb. 3 at 2:19 AM

$ACAD Trofinetide is approved by the U.S. Food and Drug Administration to treat Rett syndrome.

1 · Reply

SuperGreenToday Feb. 2 at 10:30 PM

0 · Reply

notreload_ai Feb. 2 at 10:19 PM

0 · Reply

zeustony88 Feb. 2 at 10:03 PM

$ACAD This company can’t catch a break.

1 · Reply

StocktwitsNews Feb. 2 at 9:33 PM

0 · Reply

zeustony88 Feb. 2 at 3:36 PM

$ACAD To those that added shares on the dip!

1 · Reply

SuperGreenToday Jan. 30 at 9:23 PM

$ACAD Share Price: $25.13 Contract Selected: Sep 18, 2026 $30 Calls Buy Zone: $1.70 – $2.10 Target Zone: $3.05 – $3.72 Potential Upside: 69% ROI Time to Expiration: 230 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Ham1198 Jan. 30 at 9:00 PM

$ACAD What a horrendous week

0 · Reply

BullMaven Jan. 30 at 2:54 PM

$ACAD adding 500

0 · Reply

Buster67 Jan. 29 at 6:29 PM

$ACAD Price stuck consolidating

0 · Reply

Ham1198 Jan. 28 at 9:27 PM

$ACAD WTF is going on?

0 · Reply

BullMaven Jan. 28 at 6:25 PM

$ACAD added 500

0 · Reply

Quantumup Jan. 27 at 8:17 PM

Canaccord Genuity reiterated $ACAD Buy-$32 and said, Cutting to the chase, we continue to view ACAD as undervalued on approved products alone, with an underappreciated pipeline that is not in the stock in any meaningful way at current levels. Canaccord Genuity went on to say: https://x.com/Quantumup1/status/2016243258956136717?s=20

0 · Reply

BobBijawklah Jan. 26 at 2:12 PM

$ACAD throwback to downside

0 · Reply

BillionerOfKing Jan. 23 at 9:01 PM

$ACAD Current Stock Price: $26.85 Contracts to trade: $26.0 ACAD Feb 20 2026 Call Entry: $0.10 Exit: $0.13 ROI: 25% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

zeustony88 Jan. 23 at 3:00 PM

$ACAD $30 after earnings

0 · Reply

Quantumup Jan. 16 at 2:30 PM

Piper Sandler⬆️ $AXSM's PT to $223 from $148, reiterated at an Overweight and said, 'Remaining Bullish' $ACAD $JAZZ OTSKY HLUBF HLBBF JNJ TEVA Here's more of what Piper Sandler had to say: https://x.com/Quantumup1/status/2012169826177806564?s=20

0 · Reply

SBL71 Jan. 14 at 1:48 PM

$ACAD I see the website has undergone a refresh. Or maybe I just haven’t visited it in some time.

0 · Reply

Market Cap	4.25B
Revenue (ttm)	957.80M
Net Income (ttm)	226.45M
EPS (ttm)	N/A
PE Ratio	36.71
Forward PE	34.60
Profit Margin	23.64%
Debt to Equity Ratio	0.00

Volume	1,330,300
Avg Vol	1,347,762
Day's Range	N/A - N/A
Shares Out	169.18M
Stochastic %K	40%
Beta	0.68
Analysts	Strong Sell
Price Target	$30.37